{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:32Z","timestamp":1792813532876,"version":"4.5.0"},"reference-count":203,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Parkinson disease (PD) is a complex neurodegenerative disorder, usually with multifactorial etiology. It is characterized by prominent movement disorders and non-motor symptoms. Movement disorders commonly include bradykinesia, rigidity, and resting tremor. Non-motor symptoms can include behavior disorders, sleep disturbances, hyposmia, cognitive impairment, and depression. A fraction of PD cases instead is due to Parkinsonian conditions with Mendelian inheritance. The study of the genetic causes of these phenotypes has shed light onto common pathogenetic mechanisms underlying Parkinsonian conditions. Monogenic Parkinsonisms can present autosomal dominant, autosomal recessive, or even X-linked inheritance patterns. Clinical presentations vary from forms indistinguishable from idiopathic PD to severe childhood-onset conditions with other neurological signs. We provided a comprehensive description of each condition, discussing current knowledge on genotype-phenotype correlations. Despite the broad clinical spectrum and the many genes involved, the phenotype appears to be related to the disrupted cell function and inheritance pattern, and several assumptions about genotype-phenotype correlations can be made. The interest in these assumptions is not merely speculative, in the light of novel promising targeted therapies currently under development.<\/jats:p>","DOI":"10.3389\/fneur.2021.648588","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T05:12:05Z","timestamp":1632287525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings"],"prefix":"10.3389","volume":"12","author":[{"given":"Daniele","family":"Guadagnolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Piane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Torrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pizzuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson disease epidemiology, pathology, genetics, and pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin Geriatr Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6838965","DOI":"10.1155\/2018\/6838965","article-title":"A case of Parkinson's disease with no lewy body pathology due to a homozygous exon deletion in Parkin","volume":"2018","author":"Johansen","year":"2018","journal-title":"Case Rep Neurol Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S1474-4422(06)70411-2","article-title":"Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism","volume":"5","author":"Schrag","year":"2006","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1055\/s-0031-1299782","article-title":"Genetics of Parkinson's disease","volume":"31","author":"Kumar","year":"2011","journal-title":"Semin Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson's disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-49969-7_2","article-title":"Clinical features of lrrk2 carriers with Parkinson's disease","volume":"14","author":"Kestenbaum","year":"2017","journal-title":"Adv Neurobiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Paisan-Ruiz","year":"2004","journal-title":"Neuron."},{"key":"B9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron."},{"key":"B10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1212\/01.WNL.0000172630.22804.73","article-title":"A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations","volume":"65","author":"Zabetian","year":"2005","journal-title":"Neurology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(05)17829-5","article-title":"A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease","volume":"365","author":"Di Fonzo","year":"2005","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ana.20401","article-title":"Clinical and positron emission tomography of Parkinson's disease caused by LRRK2","volume":"57","author":"Hernandez","year":"2005","journal-title":"Ann Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ana.20484","article-title":"An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family","volume":"57","author":"Funayama","year":"2005","journal-title":"Ann Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/bs.irn.2017.01.009","article-title":"Genetics of Parkinson's disease: genotype-phenotype correlations","volume":"132","author":"Koros","year":"2017","journal-title":"Int Rev Neurobiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/mds.21763","article-title":"The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease","volume":"22","author":"Li","year":"2007","journal-title":"Mov Disord"},{"key":"B16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ana.21405","article-title":"Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease","volume":"64","author":"Ross","year":"2008","journal-title":"Ann Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-49969-7_1","article-title":"Leucine-rich repeat kinase (LRRK2) genetics and Parkinson's Disease","volume":"14","author":"Monfrini","year":"2017","journal-title":"Adv Neurobiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/mds.21114","article-title":"Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques","volume":"21","author":"Simon-Sanchez","year":"2006","journal-title":"Mov Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/JPD-130312","article-title":"Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania","volume":"4","author":"De Rosa","year":"2014","journal-title":"J Parkinsons Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/mds.27059","article-title":"Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry","volume":"32","author":"Lee","year":"2017","journal-title":"Mov Disord."},{"key":"B22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1212\/WNL.0000000000000675","article-title":"LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance","volume":"83","author":"Hentati","year":"2014","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/mds.27295","article-title":"alpha-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain","volume":"33","author":"Fernandez-Santiago","year":"2018","journal-title":"Mov Disord."},{"key":"B24","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1101\/738260","article-title":"Penetrance of Parkinson's disease in LRRK2 p.G2019S carriers is modified by a polygenic risk score","volume":"35","author":"Iwaki","year":"2020","journal-title":"Mov Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/mds.23278","article-title":"Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)","volume":"25","author":"Ruiz-Martinez","year":"2010","journal-title":"Mov Disord"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2018.08.006","article-title":"Genetic background and outcome of deep brain stimulation in Parkinson's disease","volume":"64","author":"Rizzone","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.parkreldis.2015.05.002","article-title":"LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis","volume":"21","author":"Gan-Or","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2017.4019","article-title":"Progression in the LRRK2-Asssociated Parkinson disease population","volume":"75","author":"Saunders-Pullman","year":"2018","journal-title":"JAMA Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/mds.25587","article-title":"Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation","volume":"28","author":"Mirelman","year":"2013","journal-title":"Mov Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1212\/WNL.0b013e318227042d","article-title":"Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers","volume":"77","author":"Marras","year":"2011","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ana.20456","article-title":"Clinical features of LRRK2-associated Parkinson's disease in central Norway","volume":"57","author":"Aasly","year":"2005","journal-title":"Ann Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.parkreldis.2014.09.033","article-title":"Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease","volume":"21","author":"Alcalay","year":"2015","journal-title":"Parkinsonism Relat Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/bs.irn.2019.10.011","article-title":"'Atypical' Parkinson's disease - genetic","volume":"149","author":"Weissbach","year":"2019","journal-title":"Int Rev Neurobiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/mds.26815","article-title":"Study of LRRK2 variation in tauopathy: progressive supranuclear palsy and corticobasal degeneration","volume":"32","author":"Sanchez-Contreras","year":"2017","journal-title":"Mov Disord."},{"key":"B35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/mds.20875","article-title":"Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset Parkinson's disease","volume":"21","author":"Tan","year":"2006","journal-title":"Mov Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3988\/jcn.2009.5.1.29","article-title":"The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease and multiple system atrophy","volume":"5","author":"Cho","year":"2009","journal-title":"J Clin Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1002\/mds.23991","article-title":"Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers","volume":"26","author":"Brockmann","year":"2011","journal-title":"Mov Disord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.26218","article-title":"High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry","volume":"30","author":"Pyatigorskaya","year":"2015","journal-title":"Mov Disord."},{"key":"B40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3389\/fneur.2020.00395","article-title":"Clinical and imaging markers of prodromal Parkinson's disease","volume":"11","author":"Hustad","year":"2020","journal-title":"Front Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S1474-4422(17)30056-X","article-title":"Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies","volume":"16","author":"Wile","year":"2017","journal-title":"Lancet Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(18)30032-2","article-title":"The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study","volume":"17","author":"Liu","year":"2018","journal-title":"Lancet Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/jamaneurol.2014.2704","article-title":"Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease","volume":"72","author":"Kalia","year":"2015","journal-title":"JAMA Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.24962","article-title":"The neuropathology of genetic Parkinson's disease","volume":"27","author":"Poulopoulos","year":"2012","journal-title":"Mov Disord."},{"key":"B45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jnc.13593","article-title":"Genetics in Parkinson disease: mendelian versus non-Mendelian inheritance","volume":"139","author":"Hernandez","year":"2016","journal-title":"J Neurochem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat Genet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","article-title":"A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci","volume":"49","author":"Chang","year":"2017","journal-title":"Nat Genet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13024-016-0140-1","article-title":"LRRK2 at the interface of autophagosomes, endosomes and lysosomes","volume":"11","author":"Roosen","year":"2016","journal-title":"Mol Neurodegener."},{"key":"B49","doi-asserted-by":"publisher","first-page":"108022","DOI":"10.1016\/j.neuropharm.2020.108022","article-title":"Genetic causes of PD: a pathway to disease modification","volume":"170","author":"Toffoli","year":"2020","journal-title":"Neuropharmacology."},{"key":"B50","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00702-014-1179-1","article-title":"VPS35 Parkinson's disease phenotype resembles the sporadic disease","volume":"121","author":"Struhal","year":"2014","journal-title":"J Neural Transm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","article-title":"A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease","volume":"89","author":"Zimprich","year":"2011","journal-title":"Am J Hum Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ajhg.2011.06.001","article-title":"VPS35 mutations in Parkinson disease","volume":"89","author":"Vilarino-Guell","year":"2011","journal-title":"Am J Hum Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/jmedgenet-2012-101155","article-title":"A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants","volume":"49","author":"Sharma","year":"2012","journal-title":"J Med Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/mds.27527","article-title":"Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review","volume":"33","author":"Trinh","year":"2018","journal-title":"Mov Disord."},{"key":"B55","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000113680","article-title":"Etiology and pathophysiology of frontotemporal dementia, Parkinson disease and Alzheimer disease: lessons from genetic studies","volume":"5","author":"Wider","year":"2008","journal-title":"Neurodegener Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.12.001","article-title":"Role of the VPS35 D620N mutation in Parkinson's disease","volume":"36","author":"Mohan","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1126\/science.274.5290.1197","article-title":"Mapping of a gene for Parkinson's disease to chromosome 4q21-q23","volume":"274","author":"Polymeropoulos","year":"1996","journal-title":"Science."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science."},{"key":"B59","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S1474-4422(11)70213-7","article-title":"Pathological roles of alpha-synuclein in neurological disorders","volume":"10","author":"Vekrellis","year":"2011","journal-title":"Lancet Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.parkreldis.2015.09.007","article-title":"Autosomal dominant Parkinson's disease caused by SNCA duplications","volume":"22","author":"Konno","year":"2016","journal-title":"Parkinsonism Relat Disord."},{"key":"B62","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"alpha-Synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/mds.23776","article-title":"Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by alpha-synuclein triplication (Iowa kindred)","volume":"26","author":"Gwinn","year":"2011","journal-title":"Mov Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.parkreldis.2015.06.005","article-title":"Early-onset parkinsonism caused by alpha-synuclein gene triplication: clinical and genetic findings in a novel family","volume":"21","author":"Olgiati","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"B65","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/mds.25518","article-title":"Alpha-synuclein gene duplication: marked intrafamilial variability in two novel pedigrees","volume":"28","author":"Elia","year":"2013","journal-title":"Mov Disord."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/mds.22682","article-title":"Expanding the clinical phenotype of SNCA duplication carriers","volume":"24","author":"Nishioka","year":"2009","journal-title":"Mov Disord."},{"key":"B67","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/mds.25499","article-title":"The many faces of alpha-synuclein mutations","volume":"28","author":"Kasten","year":"2013","journal-title":"Mov Disord."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/jamaneurol.2014.994","article-title":"A 6.4 Mb duplication of the alpha-synuclein locus causing frontotemporal dementia and Parkinsonism: phenotype-genotype correlations","volume":"71","author":"Kara","year":"2014","journal-title":"JAMA Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/mds.25243","article-title":"A case of alpha-synuclein gene duplication presenting with head-shaking movements","volume":"28","author":"Itokawa","year":"2013","journal-title":"Mov Disord."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00702-016-1578-6","article-title":"A53T in a parkinsonian family: a clinical update of the SNCA phenotypes","volume":"123","author":"Tambasco","year":"2016","journal-title":"J Neural Transm."},{"key":"B71","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/mds.26549","article-title":"The contursi family 20 years later: intrafamilial phenotypic variability of the SNCA p.A53T mutation","volume":"31","author":"Ricciardi","year":"2016","journal-title":"Mov Disord."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/mds.26615","article-title":"Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study","volume":"31","author":"Papadimitriou","year":"2016","journal-title":"Mov Disord."},{"key":"B73","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/mds.27352","article-title":"Genotype-phenotype relations for the Parkinson's disease genes Parkin, PINK1, DJ1: MDSGene systematic review","volume":"33","author":"Kasten","year":"2018","journal-title":"Mov Disord."},{"key":"B74","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jocn.2005.11.040","article-title":"Dementia with Lewy bodies in an elderly Greek male due to alpha-synuclein gene mutation","volume":"13","author":"Morfis","year":"2006","journal-title":"J Clin Neurosci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2016.12.002","article-title":"Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene","volume":"35","author":"Bougea","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"B76","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/mds.25421","article-title":"Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease","volume":"28","author":"Appel-Cresswell","year":"2013","journal-title":"Mov Disord."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/WNL.0b013e31828727ba","article-title":"A novel alpha-synuclein missense mutation in Parkinson disease","volume":"80","author":"Proukakis","year":"2013","journal-title":"Neurology."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/WNL.56.10.1355","article-title":"Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers","volume":"56","author":"Kruger","year":"2001","journal-title":"Neurology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat Genet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann Neurol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.parkreldis.2012.08.001","article-title":"Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the alpha synuclein gene","volume":"19","author":"Tijero","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"key":"B82","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.23894","article-title":"G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome","volume":"73","author":"Lesage","year":"2013","journal-title":"Ann Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.parkreldis.2013.11.008","article-title":"Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation","volume":"20","author":"Tokutake","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1212\/NXG.0000000000000027","article-title":"Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation","volume":"1","author":"Martikainen","year":"2015","journal-title":"Neurol Genet."},{"key":"B85","doi-asserted-by":"publisher","first-page":"REVIEWS3002","DOI":"10.1186\/gb-2001-3-1-reviews3002","article-title":"The synucleins","volume":"3","author":"George","year":"2002","journal-title":"Genome Biol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev-neuro-070815-014031","article-title":"Brain disorders due to lysosomal dysfunction","volume":"39","author":"Fraldi","year":"2016","journal-title":"Annu Rev Neurosci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"a024109","DOI":"10.1101\/cshperspect.a024109","article-title":"Genetics of synucleinopathies","volume":"8","author":"Nussbaum","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1212\/WNL.54.5.1195","article-title":"Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor?","volume":"54","author":"Tan","year":"2000","journal-title":"Neurology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/hmg\/10.17.1847","article-title":"alpha-Synuclein gene haplotypes are associated with Parkinson's disease","volume":"10","author":"Farrer","year":"2001","journal-title":"Hum Mol Genet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.neurol.2018.08.004","article-title":"The genetic landscape of Parkinson's disease","volume":"174","author":"Lunati","year":"2018","journal-title":"Rev Neurol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2020.10.019","article-title":"Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease","volume":"100","author":"Saini","year":"2021","journal-title":"Neurobiol Aging."},{"key":"B92","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1474-4422(14)70266-2","article-title":"CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study","volume":"14","author":"Funayama","year":"2015","journal-title":"Lancet Neurol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.10.018","article-title":"A novel mutation of CHCHD2 p.R8H in a sporadic case of Parkinson's disease","volume":"34","author":"Ikeda","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1093\/hmg\/ddz241","article-title":"Mutations in CHCHD2 cause alpha-synuclein aggregation","volume":"28","author":"Ikeda","year":"2019","journal-title":"Hum Mol Genet."},{"key":"B95","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11910-017-0780-8","article-title":"New genes causing hereditary Parkinson's disease or parkinsonism","volume":"17","author":"Puschmann","year":"2017","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/ng.3589","article-title":"Identification of TMEM230 mutations in familial Parkinson's disease","volume":"48","author":"Deng","year":"2016","journal-title":"Nat Genet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.neuroscience.2020.11.004","article-title":"Controversy of TMEM230 Associated with Parkinson's Disease","volume":"453","author":"Wang","year":"2021","journal-title":"Neuroscience."},{"key":"B98","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/jmedgenet-2015-103616","article-title":"Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson's disease with non-motor phenotypes","volume":"53","author":"Sudhaman","year":"2016","journal-title":"J Med Genet."},{"key":"B99","doi-asserted-by":"publisher","first-page":"194 e9","DOI":"10.1016\/j.neurobiolaging.2017.01.005","article-title":"RIC3 variants are not associated with Parkinson's disease in French-Canadians and French","volume":"53","author":"Ross","year":"2017","journal-title":"Neurobiol Aging."},{"key":"B100","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(18)30408-3","article-title":"LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study","volume":"17","author":"Quadri","year":"2018","journal-title":"Lancet Neurol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/mds.27693","article-title":"LRP10 in autosomal-dominant Parkinson's disease","volume":"34","author":"Chen","year":"2019","journal-title":"Mov Disord."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1093\/brain\/awu179","article-title":"Parkinson's disease in GTP cyclohydrolase 1 mutation carriers","volume":"137","author":"Mencacci","year":"2014","journal-title":"Brain"},{"key":"B103","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1093\/brain\/awu341","article-title":"Parkinsonism in GTP cyclohydrolase 1 mutation carriers","volume":"138","author":"Guella","year":"2015","journal-title":"Brain"},{"key":"B104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-020-00212-3","article-title":"GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson's disease: a two-cohort case-control study","volume":"9","author":"Pan","year":"2020","journal-title":"Transl Neurodegener."},{"key":"B105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2017.04.003","article-title":"SCA2 family presenting as typical Parkinson's disease: 34 year follow up","volume":"40","author":"Kim","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"B106","doi-asserted-by":"publisher","first-page":"bcr0120113685","DOI":"10.1136\/bcr.01.2011.3685","article-title":"Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology","volume":"2011","author":"Takao","year":"2011","journal-title":"BMJ Case Rep."},{"key":"B107","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","article-title":"Insights into the structural biology of Gaucher disease","volume":"298","author":"Smith","year":"2017","journal-title":"Exp Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/cells8040364","article-title":"GBA, Gaucher disease, and Parkinson's disease: from genetic to clinic to new therapeutic approaches","volume":"8","author":"Riboldi","year":"2019","journal-title":"Cells"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1212\/WNL.0b013e3181b28601","article-title":"Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset","volume":"73","author":"Sidransky","year":"2009","journal-title":"Neurology."},{"key":"B110","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum Mol Genet."},{"key":"B111","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1212\/WNL.0b013e318245f476","article-title":"Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers","volume":"78","author":"Anheim","year":"2012","journal-title":"Neurology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/mds.28416","article-title":"The Rostock International Parkinson's Disease (ROPAD) study: protocol and initial findings","volume":"36","author":"Skrahina","year":"2021","journal-title":"Mov Disord."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain."},{"key":"B114","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.parkreldis.2020.04.002","article-title":"Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations","volume":"76","author":"Mangone","year":"2020","journal-title":"Parkinsonism Relat Disord."},{"key":"B115","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mdc3.12229","article-title":"The neuropsychiatric and motor profile of GBA-Associated Parkinson's disease: a review","volume":"3","author":"Pal","year":"2016","journal-title":"Mov Disord Clin Pract."},{"key":"B116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.12.014","article-title":"A \u201cdose\u201d effect of mutations in the GBA gene on Parkinson's disease phenotype","volume":"36","author":"Thaler","year":"2017","journal-title":"Parkinsonism Relat Disord."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/mds.28200","article-title":"GBA-Related Parkinson's disease: dissection of genotype-phenotype correlates in a large Italian Cohort","volume":"35","author":"Petrucci","year":"2020","journal-title":"Mov Disord"},{"key":"B119","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson's disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann Neurol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/mds.25397","article-title":"White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations","volume":"28","author":"Agosta","year":"2013","journal-title":"Mov Disord."},{"key":"B121","first-page":"213","article-title":"GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure","volume-title":"Neurology.","author":"Brockmann","year":"2012"},{"key":"B122","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/ene.12894","article-title":"GBA-associated parkinsonism and dementia: beyond alpha-synucleinopathies?","volume":"23","author":"Pilotto","year":"2016","journal-title":"Eur J Neurol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/mdc3.12406","article-title":"Progressive supranuclear palsy-like phenotype in a GBA E326K mutation carrier","volume":"4","author":"Picillo","year":"2017","journal-title":"Mov Disord Clin Pract."},{"key":"B125","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/acn3.185","article-title":"Variants associated with Gaucher disease in multiple system atrophy","volume":"2","author":"Mitsui","year":"2015","journal-title":"Ann Clin Transl Neurol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mdc3.12481","article-title":"Frequency of GBA variants in autopsy-proven multiple system atrophy","volume":"4","author":"Sklerov","year":"2017","journal-title":"Mov Disord Clin Pract."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov Disord."},{"key":"B129","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","article-title":"Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease","volume":"40","author":"Ryan","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/ejn.12872","article-title":"Evidence for a common biological pathway linking three Parkinson's disease-causing genes: Parkin, PINK1 and DJ-1","volume":"41","author":"van der Merwe","year":"2015","journal-title":"Eur J Neurosci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/jnc.13655","article-title":"The mitochondrial kinase PINK1: functions beyond mitophagy","volume":"139","author":"Voigt","year":"2016","journal-title":"J Neurochem."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/mds.25132","article-title":"Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease","volume":"27","author":"Kilarski","year":"2012","journal-title":"Mov Disord."},{"key":"B133","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/brain\/awg142","article-title":"Parkin disease: a phenotypic study of a large case series","volume":"126","author":"Khan","year":"2003","journal-title":"Brain."},{"key":"B135","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1212\/WNL.0b013e31820882aa","article-title":"Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study","volume":"76","author":"Alcalay","year":"2011","journal-title":"Neurology."},{"key":"B136","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jamaneurol.2013.172","article-title":"Parkin disease: a clinicopathologic entity?","volume":"70","author":"Doherty","year":"2013","journal-title":"JAMA Neurol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ana.1132","article-title":"Lewy bodies and parkinsonism in families with parkin mutations","volume":"50","author":"Farrer","year":"2001","journal-title":"Ann Neurol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/humu.22808","article-title":"Structural and functional impact of Parkinson disease-associated mutations in the E3 Ubiquitin Ligase Parkin","volume":"36","author":"Fiesel","year":"2015","journal-title":"Hum Mutat."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1093\/hmg\/ddi292","article-title":"Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin","volume":"14","author":"Sriram","year":"2005","journal-title":"Hum Mol Genet."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awq051","article-title":"PINK1-linked parkinsonism is associated with Lewy body pathology","volume":"133","author":"Samaranch","year":"2010","journal-title":"Brain."},{"key":"B141","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ana.20666","article-title":"DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex","volume":"58","author":"Annesi","year":"2005","journal-title":"Ann Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/brain\/aww080","article-title":"DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology","volume":"139","author":"Taipa","year":"2016","journal-title":"Brain."},{"key":"B143","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S1474-4422(07)70174-6","article-title":"Deciphering the role of heterozygous mutations in genes associated with parkinsonism","volume":"6","author":"Klein","year":"2007","journal-title":"Lancet Neurol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/humu.20719","article-title":"PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum","volume":"29","author":"Marongiu","year":"2008","journal-title":"Hum Mutat."},{"key":"B145","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.parkreldis.2008.11.014","article-title":"Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers","volume":"15","author":"Bruggemann","year":"2009","journal-title":"Parkinsonism Relat Disord."},{"key":"B146","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/mds.22817","article-title":"Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study","volume":"24","author":"Pavese","year":"2009","journal-title":"Mov Disord."},{"key":"B147","doi-asserted-by":"publisher","first-page":"S703","DOI":"10.1002\/mds.22635","article-title":"Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach","volume":"24","author":"van Nuenen","year":"2009","journal-title":"Mov Disord."},{"key":"B148","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ajhg.2016.01.014","article-title":"Loss of VPS13C function in autosomal-recessive Parkinsonism causes mitochondrial dysfunction and increases PINK1\/Parkin-dependent mitophagy","volume":"98","author":"Lesage","year":"2016","journal-title":"Am J Hum Genet."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/mds.26682","article-title":"VPS13C-another hint at mitochondrial dysfunction in familial Parkinson's disease","volume":"31","author":"Schreglmann","year":"2016","journal-title":"Mov Disord."},{"key":"B150","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/mds.26824","article-title":"PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism","volume":"32","author":"Khodadadi","year":"2017","journal-title":"Mov Disord."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/mds.27501","article-title":"PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability","volume":"33","author":"Kuipers","year":"2018","journal-title":"Mov Disord."},{"key":"B152","doi-asserted-by":"publisher","first-page":"188e15","DOI":"10.1016\/j.neurobiolaging.2020.09.002","article-title":"Lack of PTRHD1 mutation in patients with young-onset and familial Parkinson's disease in a Taiwanese population","volume":"100","author":"Chen","year":"2021","journal-title":"Neurobiol Aging."},{"key":"B153","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.parkreldis.2019.06.025","article-title":"Juvenile Parkinsonism: differential diagnosis, genetics, and treatment","volume":"67","author":"Niemann","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"B154","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/jmedgenet-2015-103459","article-title":"Discovery of a frameshift mutation in podocalyxin-like (PODXL) gene, coding for a neural adhesion molecule, as causal for autosomal-recessive juvenile Parkinsonism","volume":"53","author":"Sudhaman","year":"2016","journal-title":"J Med Genet."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e36458","DOI":"10.1371\/journal.pone.0036458","article-title":"A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism","volume":"7","author":"Edvardson","year":"2012","journal-title":"PLoS ONE."},{"key":"B156","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/ana.24553","article-title":"DNAJC6 mutations associated with early-onset Parkinson's disease","volume":"79","author":"Olgiati","year":"2016","journal-title":"Ann Neurol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ana.24591","article-title":"A Novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease","volume":"79","author":"Elsayed","year":"2016","journal-title":"Ann Neurol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.parkreldis.2012.11.006","article-title":"DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability","volume":"19","author":"Koroglu","year":"2013","journal-title":"Parkinsonism Relat Disord."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/humu.22373","article-title":"Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism","volume":"34","author":"Quadri","year":"2013","journal-title":"Hum Mutat."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/humu.22372","article-title":"The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures","volume":"34","author":"Krebs","year":"2013","journal-title":"Hum Mutat."},{"key":"B161","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.parkreldis.2018.11.020","article-title":"Clonazepam improves the symptoms of two siblings with novel variants in the SYNJ1 gene","volume":"62","author":"Hong","year":"2019","journal-title":"Parkinsonism Relat Disord."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/brain\/aww180","article-title":"Loss of SYNJ1 dual phosphatase activity leads to early onset refractory seizures and progressive neurological decline","volume":"139","author":"Hardies","year":"2016","journal-title":"Brain."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1222 e1","DOI":"10.1016\/j.neurobiolaging.2014.09.005","article-title":"Homozygous nonsense mutation in SYNJ1 associated with intractable epilepsy and tau pathology","volume":"36","author":"Dyment","year":"2015","journal-title":"Neurobiol Aging."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ng1884","article-title":"Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase","volume":"38","author":"Ramirez","year":"2006","journal-title":"Nat Genet."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1212\/01.wnl.0000260963.08711.08","article-title":"ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease","volume":"68","author":"Di Fonzo","year":"2007","journal-title":"Neurology."},{"key":"B166","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/mds.22947","article-title":"ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation","volume":"25","author":"Schneider","year":"2010","journal-title":"Mov Disord."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e1052","DOI":"10.1002\/mgg3.1052","article-title":"Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype","volume":"8","author":"Estiar","year":"2020","journal-title":"Mol Genet Genomic Med."},{"key":"B168","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1093\/hmg\/dds089","article-title":"Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis","volume":"21","author":"Bras","year":"2012","journal-title":"Hum Mol Genet."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/mds.23221","article-title":"Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations","volume":"25","author":"Paisan-Ruiz","year":"2010","journal-title":"Mov Disord."},{"key":"B170","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13104-016-2102-7","article-title":"Clinical heterogeneity of PLA2G6-related Parkinsonism: analysis of two Saudi families","volume":"9","author":"Bohlega","year":"2016","journal-title":"BMC Res Notes."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3389\/fneur.2018.01100","article-title":"PLA2G6-associated neurodegeneration (PLAN): review of clinical phenotypes and genotypes","volume":"9","author":"Guo","year":"2018","journal-title":"Front Neurol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/01.wnl.0000310986.48286.8e","article-title":"Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN)","volume":"70","author":"Kurian","year":"2008","journal-title":"Neurology."},{"key":"B173","doi-asserted-by":"publisher","first-page":"e12897","DOI":"10.1371\/journal.pone.0012897","article-title":"Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism","volume":"5","author":"Engel","year":"2010","journal-title":"PLoS ONE."},{"key":"B174","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/01.wnl.0000338144.10967.2b","article-title":"FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome","volume":"72","author":"Di Fonzo","year":"2009","journal-title":"Neurology."},{"key":"B175","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.parkreldis.2017.11.332","article-title":"Juvenile-onset parkinsonism with pyramidal signs due to compound heterozygous mutations in the F-Box only protein 7 gene","volume":"47","author":"Wei","year":"2018","journal-title":"Parkinsonism Relat Disord."},{"key":"B176","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ajhg.2014.10.015","article-title":"Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with alpha-synuclein pathology","volume":"95","author":"Wilson","year":"2014","journal-title":"Am J Hum Genet."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/mds.26828","article-title":"A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification","volume":"31","author":"Shi","year":"2016","journal-title":"Mov Disord."},{"key":"B178","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1212\/NXG.0000000000000009","article-title":"Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease","volume":"1","author":"Lesage","year":"2015","journal-title":"Neurol Genet."},{"key":"B179","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-015-0045-4","article-title":"The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease","volume":"10","author":"Mata","year":"2015","journal-title":"Mol Neurodegener."},{"key":"B180","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fneur.2020.00523","article-title":"Genetic analysis of RAB39B in an early-onset Parkinson's disease Cohort","volume":"11","author":"Gao","year":"2020","journal-title":"Front Neurol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain."},{"key":"B182","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/mds.27614","article-title":"The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease","volume":"34","author":"Bandres-Ciga","year":"2019","journal-title":"Mov Disord."},{"key":"B183","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1083\/jcb.201402104","article-title":"PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity","volume":"205","author":"Kane","year":"2014","journal-title":"J Cell Biol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/nature04779","article-title":"Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin","volume":"441","author":"Clark","year":"2006","journal-title":"Nature."},{"key":"B185","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/mds.22713","article-title":"DJ-1, PINK1, and their effects on mitochondrial pathways","volume":"25","author":"Cookson","year":"2010","journal-title":"Mov Disord."},{"key":"B186","doi-asserted-by":"publisher","first-page":"104782","DOI":"10.1016\/j.nbd.2020.104782","article-title":"Genetics of Parkinson's disease: an introspection of its journey towards precision medicine","volume":"137","author":"Bandres-Ciga","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B187","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ana.10113","article-title":"A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1","volume":"51","author":"Funayama","year":"2002","journal-title":"Ann Neurol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nn.3361","article-title":"Dangerous duet: LRRK2 and alpha-synuclein jam at CMA","volume":"16","author":"Yue","year":"2013","journal-title":"Nat Neurosci."},{"key":"B189","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1073\/pnas.1112368109","article-title":"Loss of P-type ATPase ATP13A2\/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration","volume":"109","author":"Dehay","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B190","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1177\/1073858417748875","article-title":"Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications","volume":"24","author":"Balestrino","year":"2018","journal-title":"Neuroscientist."},{"key":"B191","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/brain\/aws318","article-title":"Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort","volume":"136","author":"Winder-Rhodes","year":"2013","journal-title":"Brain."},{"key":"B192","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1326-3-19","article-title":"In vivo silencing of alpha-synuclein using naked siRNA","volume":"3","author":"Lewis","year":"2008","journal-title":"Mol Neurodegener."},{"key":"B193","doi-asserted-by":"publisher","first-page":"e12122","DOI":"10.1371\/journal.pone.0012122","article-title":"Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra","volume":"5","author":"McCormack","year":"2010","journal-title":"PLoS ONE."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov Disord."},{"key":"B195","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41531-018-0062-4","article-title":"Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson's disease model","volume":"4","author":"Chatterjee","year":"2018","journal-title":"NPJ Parkinsons Dis."},{"key":"B196","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3233\/JPD-189004","article-title":"Clinical trial highlights: targetting alpha-synuclein","volume":"9","author":"McFarthing","year":"2019","journal-title":"J Parkinsons Dis."},{"key":"B197","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1016\/j.jmb.2014.04.015","article-title":"A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies","volume":"426","author":"Krishnan","year":"2014","journal-title":"J Mol Biol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"108843","DOI":"10.1016\/j.biopha.2019.108843","article-title":"Progress of immunotherapy of anti-alpha-synuclein in Parkinson's disease","volume":"115","author":"Wang","year":"2019","journal-title":"Biomed Pharmacother."},{"key":"B199","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"B200","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tox.2018.01.003","article-title":"PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats","volume":"395","author":"Andersen","year":"2018","journal-title":"Toxicology."},{"key":"B201","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"B202","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-Pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J Med Chem."},{"key":"B203","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JDP-201981","article-title":"Mitochondria and Parkinson's disease: clinical, molecular, and translational aspects","volume":"11","author":"Borsche","year":"2021","journal-title":"J Parkinsons Dis."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.648588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T05:12:10Z","timestamp":1632287530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.648588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":203,"alternative-id":["10.3389\/fneur.2021.648588"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.648588","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"648588"}}